Neurogene Inc.
NASDAQ Global MarketTotal Valuation
Neurogene Inc. carries a market capitalization of 521.73M, placing it among publicly traded companies globally. Its enterprise value stands at 200.00M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 521.73M |
| Enterprise Value | 200.00M |
Share Statistics
Neurogene Inc. currently has 15.62M shares outstanding.
| Shares Outstanding | 15.62M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -1.13 |
| P/TBV Ratio | 1.82 |
| P/FCF Ratio | -5.30 |
| P/OCF Ratio | -5.26 |
Financial Position
Neurogene Inc. maintains a current ratio of 13.08, meaning it holds 13.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 4.01, indicating elevated leverage, while an interest coverage ratio of -35,857.67 demonstrates limited ability to service its debt obligations.
| Current Ratio | 13.08 |
| Quick Ratio | 12.90 |
| Debt / Equity | 4.01 |
| Debt / EBITDA | -0.09 |
| Interest Coverage | -35,857.67 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -34.10 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Neurogene Inc.'s stock has gained approximately 69.31795% over the past 52 weeks. The 50-day moving average sits at 29.15, while the 200-day moving average is 23.72.
| Beta (5Y) | N/A |
| 52-Week Price Change | 69.31795% |
| 50-Day Moving Average | 29.15 |
| 200-Day Moving Average | 23.72 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -107.57M, while operating income came in at -110.76M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -110.76M |
| Pretax Income | -98.64M |
| Net Income | -98.64M |
| EBITDA | -107.57M |
| EBIT | -110.76M |
| Earnings Per Share (EPS) | -4.59 |
Balance Sheet
Neurogene Inc. holds 243.18M in cash and equivalents against 9.54M in total debt, resulting in a net debt position of -124.16M. Total book value stands at -383.58M, with working capital of 227.88M providing operational flexibility.
| Cash & Cash Equivalents | 243.18M |
| Total Debt | 9.54M |
| Net Debt | -124.16M |
| Equity (Book Value) | -383.58M |
| Book Value Per Share | -17.83 |
| Working Capital | 227.88M |
Cash Flow
Neurogene Inc. produced -82.52M in operating cash flow over the past twelve months. After subtracting -684,000.00 in capital expenditures, free cash flow totaled -83.20M - equivalent to -3.87 per share.
| Operating Cash Flow | -82.52M |
| Capital Expenditures | -684,000.00 |
| Free Cash Flow | -83.20M |
| FCF Per Share | -3.87 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -7.06 |
| FCF Yield | -18.87 |
Stock Splits
Neurogene Inc.'s most recent stock split took place on December 19, 2023 with a 4:1 split ratio.
| Last Split Date | 12/19/2023 |
| Split Ratio | 4:1 |
Scores
Neurogene Inc. posts an Altman Z-Score of 7.87, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 7.87 |